Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 8;11(1):150.
doi: 10.1186/s13023-016-0528-6.

The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseases

M K Javaid  1   2 , L Forestier-Zhang  3 , L Watts  3 , A Turner  3 , C Ponte  3 , H Teare  4 , D Gray  3 , N Gray  3 , R Popert  3 , J Hogg  3 , J Barrett  3 , R Pinedo-Villanueva  3 , C Cooper  3   5 , R Eastell  6 , N Bishop  7 , R Luqmani  3 , P Wordsworth  3 , J Kaye  4
Affiliations

The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseases

M K Javaid et al. Orphanet J Rare Dis. .

Abstract

Background: Research into rare diseases is becoming more common, with recognition of the significant diagnostic and therapeutic care gaps. Registries are considered a key research methodology to address rare diseases. This report describes the structure of the Rare UK Diseases Study (RUDY) platform that aims to improve research processes and address many of the challenges of carrying out rare musculoskeletal disease research. RUDY is an internet-based platform with online registration, initial verbal consent, online capture of patient reported outcome measures and events within a dynamic consent framework. The database structure, security and governance framework are described.

Results: There have been 380 participants recruited into RUDY with completed questionnaire rates in excess of 50 %. There has been one withdrawal and two participants have amended their consent options.

Conclusions: The strengths of RUDY include low burden for the clinical team, low research administration costs with high participant recruitment and ease of data collection and access. This platform has the potential to be used as the model for other rare diseases globally.

Keywords: Database management systems; Dynamic consent; Patient reported outcome measures; Rare diseases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic of interactions between patient groups, patients, participants, clinicians and academics within the RUDY Study
Fig. 2
Fig. 2
Homepage of the RUDYstudy.org
See this image and copyright information in PMC

References

    1. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039–41. doi: 10.1016/S0140-6736(08)60872-7. - DOI - PubMed
    1. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6. doi: 10.1016/j.ymgme.2008.10.003. - DOI - PMC - PubMed
    1. Wastfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260(1):1–10. doi: 10.1111/j.1365-2796.2006.01666.x. - DOI - PubMed
    1. Cavero-Carbonell C, Gras-Colomer E, Guaita-Calatrava R, Lopez-Briones C, Amoros R, Abaitua I, et al. Consensus on the criteria needed for creating a rare-disease patient registry. A Delphi study. J Public Health (Oxf). 2015;38(2):e178–e186. - PubMed
    1. Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50. doi: 10.1177/0883073813495959. - DOI - PMC - PubMed